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Abstract
Introduction Ductal carcinoma in situ (DCIS) is a noninvasive
premalignant lesion and is considered a precursor to invasive
carcinoma. DCIS accounts for nearly 20% of newly diagnosed
breast cancer, but the lack of experimentally amenable in vivo
DCIS models hinders the development of treatment strategies.
Here, we demonstrate the utility of a mouse transplantation
model of DCIS for chemoprevention studies using selective
estrogen receptor modulators (SERMs). This model consists of
a set of serially transplanted lines of genetically engineered
mouse mammary intraepithelial neoplasia (MIN) outgrowth
(MIN-O) tissue that have stable characteristics. We studied the
ovarian-hormone-responsiveness of one of the lines with a
particular focus on the effects of two related SERMs, tamoxifen
and ospemifene.
Methods The estrogen receptor (ER) status and ovarian-
hormone-dependence of the mouse MIN outgrowth tissue were
determined by immunohistochemistry and ovarian ablation. The
effects of tamoxifen and ospemifene on the growth and
tumorigenesis of MIN outgrowth were assessed at 3 and 10
weeks after transplantation. The effects on ER status, cell
proliferation, and apoptosis were studied with
immunohistochemistry.
Results The MIN-O was ER-positive and ovarian ablation
resulted in reduced MIN-O growth and tumor development.
Likewise, tamoxifen and ospemifene treatments decreased the
MIN growth and tumor incidence in comparison with the control
(P < 0.01). Both SERMs significantly decreased cell
proliferation. Between the two SERM treatment groups, there
were no statistically significant differences in MIN-O size, tumor
latency, or proliferation rate. In contrast, the ospemifene
treatment significantly increased ER levels while tamoxifen
significantly decreased them.
Conclusion Tamoxifen and ospemifene inhibit the growth of
premalignant mammary lesions and the progression to invasive
carcinoma in a transplantable mouse model of DCIS. The
inhibitory effects of these two SERMs are similar except for their
effects on ER modulation. These differences in ER modulation
may suggest different mechanisms of action between the two
related SERMs and may portend different long-term outcomes.
These data demonstrate the value of this model system for
preclinical testing of antiestrogen or other therapies designed to
prevent or delay the malignant transformation of premalignant
mammary lesions in chemoprevention.R881
DCIS = ductal carcinoma in situ; DMBA = dimethylbenz [a]anthracene; DMSO = dimethyl sulfoxide; ER = estrogen receptor; FDA = Food and Drug 
Administration; H & E = hematoxylin and eosin; HPLC = high-performance liquid chromatography; MIN = mammary intraepithelial neoplasia; MIN-O 
= mammary intraepithelial neoplasia outgrowth; MMTV = mouse mammary tumor virus; PyV-mT = polyomavirus middle T; SERM = selective estrogen 
receptor modulator.
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Improvements in mammography screening now permit the
detection of early breast lesions such as ductal carcinoma in
situ (DCIS). These lesions represent the most rapidly growing
subgroup of breast cancers and comprise nearly 20% of all
newly diagnosed cases of breast cancer. Although DCIS is
considered a noninvasive lesion, if it is left untreated, invasive
carcinoma will develop in 40% to 50% of DCIS cases [1].
Thus, effective treatment of DCIS could substantially reduce
the incidence of invasive breast cancer. However, developing
strategies for DCIS treatment has been difficult, partly
because of a lack of an experimentally amenable in vivo model.
Over the past several years, our group has developed and
characterized a mouse model for DCIS that shares biological,
morphological, and molecular characteristics with human
DCIS [2,3]. In addition, this model meets the criteria for mouse
premalignant mammary intraepithelial lesions set by the NIH
Annapolis Pathology Panel of the Workshop on Mouse Mod-
els of Human Breast Cancer [4]. The definition of mammary
intraepithelial neoplasia (MIN) is based on morphological cri-
teria and the biological behavior of the lesions assessed by
ectopic and orthotopic transplantation in syngeneic recipient
mice. A MIN lesion is incapable of ectopic growth but capable
of orthotopic growth (in a gland-cleared mammary fat pad),
and this growth has a consistently high rate of transformation
to 'malignancy', defined as the ability to grow in ectopic and
orthotopic locations.
The model described here was derived by transplanting focal
mammary lesions from mouse mammary tumor virus (MMTV)
polyomavirus middle T (PyV-mT) transgenic mice to syngeneic
wild-type host mammary fat pads. The Tg(PyV-mT) model is an
attractive human breast cancer model not only because of its
molecular similarities to the human breast cancer, but also
because of the similar morphology and histology to human
breast cancer [5]. PyV-mT is a membrane-bound viral onco-
gene. The signaling pathways activated by PyV-mT include
those of Ras, Shc, and phosphotidylinositol 3-kinase, which
are frequently activated in human breast cancer (reviewed in
[6]) and are also activated by ErbB2 (Her2/neu), a receptor
tyrosine kinase that is overexpressed in 30% of breast cancer
and is associated with poor outcome [7]. The molecular profile
of Tg(PyV-mT) mouse mammary tumors is more similar to that
of Neu/ErbB2 and myc transgenic mouse mammary tumors
than to other transgenic mouse tumors [8]. The histology of
Tg(PyV-mT) mammary tumors resembles Tg(Neu/ErbB2)
mammary tumors and human breast cancer much more closely
than other transgenic mammary tumors [9]. Stages of Tg(PyV-
mT) mammary tumor development also recapitulate human
breast cancer progression histologically as well as in the
expression of biomarkers associated with poor prognosis [5].
Stable mammary intraepithelial neoplasia outgrowth (MIN-O)
lines have been established by microscopically identifying and
dissecting premalignant dysplastic foci from Tg(PyV-mT)
mammary fat pads and serially transplanting them into the
gland-cleared mammary fat pads of wild-type FVB/N host mice
[2,10]. The transplanted MIN tissue grows to fill the host mam-
mary fat pad, and after a certain latency period, tumor foci arise
within the MIN-Os. The lines have been maintained over sev-
eral years by serial transplantation of MIN-Os to new host fat
pads. Therefore, the MIN-O lines provide the biology of the
tumor progression found in the original Tg(PyV-mT) mammary
fat pad in an experimentally reproducible setting.
Estrogen exposure is an important breast cancer risk factor.
Seventy percent of breast cancers express the estrogen
receptor (ER) [11]. The absence of ER in breast cancer is
associated with poor prognosis. In the Tg(PyV-mT) model, rel-
atively high numbers of ER-positive cells are found in the early
MIN stage, but invasive tumorigenesis is associated with loss
of ER [5]. In a Tg(PyV-mT) tumor explant model with a low to
moderate expression of ER, tumor grew slower in ovariect-
omized animals than in intact animals, whereas estrogen sup-
plementation stimulated rapid tumor growth, suggesting that
this model is sensitive to estrogen level [12].
In ER-positive human breast cancer, a selective estrogen
receptor modulator (SERM), tamoxifen, is typically used in
adjuvant therapy. The US Food and Drug Administration (FDA)
has approved tamoxifen, and studies have shown that in ER-
positive cancer, treatment for 5 years reduces recurrence by
47% and the risk of death by 26% [13]. Unfortunately,
tamoxifen therapy is associated with undesirable side effects,
including endometrial cancer, thromboembolic events, and
liver cancer (as seen in animal models [14]) as well as hot
flashes, insomnia, vaginal discharge, and vaginal dryness [15].
Therefore, the search for other SERMs has continued.
Recently, third-generation aromatase inhibitors, which block
the conversion of androgens to estrogens, have been shown
to be potentially more efficacious than tamoxifen [15], but
recently reported side effects, including bone loss, joint pain,
and cardiac events, have caused concern [16].
Therefore, a model that recapitulates human DCIS, with pro-
gression to invasive carcinoma with demonstrated ER-positiv-
ity and estrogen-dependency would allow for preclinical
studies to assess the efficacy of this new generation of
SERMs and aromatase inhibitors. Here we have used one
transplantable MIN-O line, 8w-B, because it has a relatively
short tumor latency, has uniform histopathology, has consist-
ent molecular architecture over multiple transplant genera-
tions, and is ER-positive [3]. To further explore the ovarian-
hormone-dependency of the MIN-O line, growth of the MIN-O
transplant and tumor incidence were determined after ovariec-
tomy. To demonstrate the utility of this model in antiestrogen
therapy, we treated the animals with tamoxifen, the gold stand-
ard and FDA-approved adjuvant therapeutic for ER-positive
cancer, and a less extensively studied SERM, ospemifene.
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enyl)phenoxy]ethanol), is structurally similar to tamoxifen but
has a more benign side-effect profile, including proestrogenic
in the bone and neutral in the endometrium [17]. It is currently
in phase III clinical trials for the urogenital sequelae, but there
are limited data demonstrating its effectiveness in breast can-
cer. In our study, both tamoxifen and ospemifene treatments
resulted in a similar level of suppression of the MIN-O growth
and tumor incidence. In addition, Ki-67, a marker for prolifera-
tion and a potential efficacy biomarker, showed decreased
expression with treatment. Interestingly, we found that
tamoxifen treatment decreased the ER status of the MIN-Os
while ospemifene treatment did not. This suggests that these
two related SERMs act differently and that there may be differ-
ential long-term effects. Overall, these studies show that this
MIN model can be used for preclinical trials and is a suitable
preclinical model for antiestrogen therapy.
Materials and methods
Mice
Standard techniques for mammary gland clearing and trans-
plantation, and the establishment and characterization of the
MIN-O line, have been described previously [2]. Three-week-
old FVB/J female mice were purchased from Charles River
Laboratories (Wilmington, MA, USA). The surgery and treat-
ments were carried out in the animal housing facility on the
University of California Davis campus following the approved
procedures.
Ovariectomy study
8w-B premalignant MIN-O tissue (1 mm3) [2] was trans-
planted in the gland-cleared no.4 fat pads of 3-week-old virgin
FVB/J female mice. In addition, at the time of transplantation,
the experimental group (8 animals) was ovariectomized. The
control group (4 animals) received the transplants and sham
surgery without ovariectomy. The tumor latency was measured
by weekly palpation. The extent of MIN-O growth was
assessed at 5 weeks after transplantation by exposing the
transplanted mammary fat pad and visually inspecting the
transplanted MIN-Os under a dissecting microscope. The ani-
mals were palpated weekly until a tumor was detected. The
experiment was concluded at day 99.
Chemoprevention study
SERM treatments were prepared by suspending ospemifene
(Hormos Medical Corporation, Turku, Finland) or tamoxifen cit-
rate (Orion Corporation, Orion-Pharma, Espoo, Finland) in
dimethyl sulfoxide (DMSO) and then diluting with peanut oil to
the final concentration of 1% DMSO. Animals received 50 mg/
kg of tamoxifen or ospemifene in 100 µl peanut oil daily by oral
gavage. These concentrations have been shown to be effec-
tive in mice (MW DeGregorio, unpublished results). The con-
trol group received 100 µl of 1% DMSO in peanut oil.
Three-week-old gland-cleared FVB/J female mice were treated
with tamoxifen, ospemifene, or vehicle control starting 1 week
before the MIN-O transplantation, ensuring therapeutic levels
of the SERM at the time of transplantation. In the first experi-
ment, animals (n = 4 per group) were sacrificed 3 weeks after
transplantation. In the second experiment, animals (n = 9 for
tamoxifen, n = 12 for ospemifene, and n = 13 for control) were
sacrificed 10 weeks after transplantation. For both experi-
ments, at the time of sacrifice, the MIN-O growth was
recorded as gross percentage of area filled in the fat pad (%
fat pad filled), and the tumor foci were measured in two dimen-
sions under a stereomicroscope. Each fat pad was fixed in
10% formalin for histological analysis. Tumor incidence was
assessed from histological sections of each fat pad. In addi-
tion, serum was obtained from each animal for HPLC analysis.
At autopsy, each mouse was assessed for any other
abnormalities.
Histology
Methods for whole-mount preparation of fixed mammary fat
pads and immunohistochemistry on the paraffin-embedded fat
pads have been described previously [2]. The following pri-
mary antibodies were used with the VECTASTAIN ABC Elite
Kit (Vector Laboratories, Burlingame, CA, USA): rabbit anti-ER
(1:600, LabVision, Fremont, CA, USA), anti-Ki-67, anti-
cleaved caspase-3 (1:250, Promega, Madison, WI, USA), and
anti-PyV-mT (B4Rat7; 1:50; Dr Gernot Walter, UC San
Diego).
ER positivity was scored according to the method of Harvey
and colleagues [18]. The frequency of ER-positive cells was
scored on a scale of 0 to 5, where 0 = no ER staining, 1 = up
to 1% of cells with ER positivity, 2 = 1% to 10%, 3 = 11% to
33% (one-third), 4 = 34% to 66%, and 5 = more than two-
thirds of cells with ER positivity. The intensity of staining was
scored on a scale of 0 to 3, where 0 = no staining, 1 = weak
staining, 2 = intermediate staining, and 3 = strong staining.
The final ER score was calculated by adding the frequency
score and the intensity score. ER staining in proliferating edge
and differentiated center zone was scored separately for each
MIN-Os (n = 17 for control, n = 16 for ospemifene, and n =
11 for tamoxifen).
For quantification of Ki-67 and cleaved caspase-3 staining, the
positive nuclei were counted and the total epithelial area was
measured in Image-Pro PLUS (MediaCybernetics, Silver
Spring, MD, USA) from at least four different 40×-objective
images from each treatment group. The number of positive
nuclei was normalized to the epithelial area of each image.
HPLC analysis
Ospemifene and tamoxifen serum samples were quantified
using a previously published assay [19,20]. Toremifene citrate
(5 µg/ml in methanol (Orion Corporation, Orion Pharma,
Espoo, Finland) was used as the internal standard for the
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in methanol; Sigma, St Louis, MO, USA) served as the internal
standard for the tamoxifen and control group samples.
Statistical analysis
An unpaired t-test was used for the MIN-O size analysis in the
ovariectomy and SERM treatment experiments and immuno-
histochemistry analysis. For the analysis of tumor latency in the
ovariectomy study, a log-rank test was used. For the tumor
incidence analysis, Fisher's exact test was used. All statistical
analysis was performed using GraphPad Prism version 4.00
for Windows (GraphPad Software, San Diego, CA, USA).
Results
MIN-O lesions are ovarian hormone-sensitive
The ovarian-hormone-dependence of the MIN-O was
assessed by ovariectomizing the host FVB/J females. The
sizes of the MIN-Os were measured as percentage of fat pad
filled 5 weeks after transplantation. The MIN-Os in the ovariec-
tomized animals were one-third the size of those in the control
animals (P < 0.0001; Table 1; Fig. 1a) and tumor incidence
was decreased (100% tumor free) as compared to the nono-
variectomized controls (25% tumor free) at 5 weeks after
transplantation. The ovariectomy prolonged the tumor latency
of the 8w-B MIN-O line significantly (P < 0.0001) from TE50
(the time for 50% of the transplanted mammary fat pads to
produce palpable tumors) of 6.6 weeks to 10.1 weeks (Table
1; Fig. 1b).
Since ER status is an important classifier of breast cancer, ER
expression of the MIN-Os and tumors arising from the MIN-Os
was analyzed by immunohistochemistry. Immunochemically
detected ER positivity was most strongly present in the area
closest to the proliferating edge of the MIN-Os (proliferating
zone; Fig. 1c), where large clusters of ER-positive cells were
found (Fig. 1d left), while in the center of the MIN-Os, where
cells are more differentiated, ER-positive cells were present
but more scattered. In the tumors, there were fewer ER-posi-
tive cells and these were distributed in a random fashion that
has been seen in Tg(PyV-mT) tumors (Fig. 1d, right) [5]. In
ovariectomized animals, ER expression remained without obvi-
ous change in intensity and distribution in the MIN-O tissues
(data not shown).
Table 1
Effect of ovarian ablation in mice on MIN-O growth in fat pads
Mice MIN-O size at 5 weeks after transplantation Tumor latency
%FPF (no.) Relative to control P TE50 (weeks) P
Control 67.50 ± 12.58 (4) 1 0.0001 6.60 0.0001
Ovariectomized 22.86 ± 7.56 (7) 0.34 10.10
%FPF, percentage of fat pad filled; MIN-O, mammary intraepithelial neoplasia outgrowth; TE50, time for 50% of the transplanted mammary fat 
pads to produce palpable tumors.
Figure 1
Effect of ovarian hormone on the development of mammary intraepithe-lial neoplasi  outgrowths (MIN-Os) and tu ors
lial neoplasia outgrowths (MIN-Os) and tumors. (a) Whole-mount 
images, from intact (top panel) and ovariectomized (bottom panel) 
murine host mammary fat pads into which 8w-B premalignant MIN-O 
tissue had been transplanted. MIN-O (dark blue) is significantly larger in 
the intact host fat pad at 5 weeks after transplantation than in the ova-
riectomized host fat pad. Lymph node (L) is seen at the left side of the 
MIN-O. (b) Effect of ovarian ablation on the 8w-B MIN-O line tumor 
development. Time to palpable tumor was significantly longer in ova-
riectomized mice (n = 8) than in the intact ones (n = 4). (c) Immunohis-
tochemical staining of the proliferation marker Ki-67 on MIN-O (center 
and right). The growing edge of the MIN-O is highly proliferative, as 
seen by intense Ki-67 staining (brown, 10× field, center). A 20× field of 
the boxed area is shown on the right. The proliferative area (P) is indi-
cated. Corresponding H & E staining is shown on the left. (d) Immuno-
histochemical staining of estrogen receptor (ER)-α on MIN-O (left) and 
tumor (right) from 8w-B-line animals at 10 weeks after transplantation. 
Areas with strong nuclear ER staining as well as cytoplasmic staining 
were often found in the MIN-O tissue (left). In general, ER staining in 
tumor tissue was less intense and less frequent (right). ovx, 
ovariectomized.
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The effect of SERMs on the MIN-O development was evalu-
ated by treating MIN-O-transplanted animals with either
tamoxifen or ospemifene. In order to determine the effect on
the MIN-O growth, rather than the effect on tumor incidence,
SERM-treated animals were humanely sacrificed at 3 weeks
after transplantation, before tumors typically develop. While all
MIN-O transplants, regardless of the treatment type, had
clearly increased in size from the initial transplant, the SERM-
treated animals had significantly smaller MIN-Os than the
untreated animals (P < 0.0001; Fig. 2a). On the other hand,
the MIN-O sizes were not statistically different between the
two SERM groups. At the time of termination at 3 weeks after
transplant, no tumor foci were seen in any of the groups.
The effect of the long-term SERM treatment on tumorigenesis
was evaluated at 10 weeks after transplantation (Fig. 2b–d).
Typically, by 10 weeks the transplanted MIN-O will fill the
majority of the fat pad, and tumor foci can be found within most
of the MIN-Os. In this study, tumors were identified in 21 of the
25 control mammary fat pads, 8 of the 23 ospemifene-treated
mammary fat pads, and 6 of the 18 tamoxifen-treated mam-
mary fat pads at 10 weeks after transplantation (Fig. 2b). The
tumor incidences in both SERM groups were significantly
lower than in the control group. There was no significant differ-
ence in the tumor incidences between the two SERM-treated
Figure 2
Effect of the selective estrogen receptor modulator (SERM) treatmentsl i tr  r t r odulator ( E ) treat ents. (a) Relative amount of mammary intraepithelial neoplasia outgrowth (MIN-O) 
tissue at 3 weeks after transplantation. The amount of MIN-O tissue in the fat pads of mice treated with ospemifene or tamoxifen was significantly 
less than that of untreated mice (P < 0.0001). (b) Tumor incidence of the MIN-O-transplanted fat pads at 10 weeks after transplantation. The actual 
number of tumor-bearing fat pads is shown within each bar. Tumor incidence in SERM-treated fat pads was significantly lower than in the untreated 
fat pads (P = 0.0009 for ospemifene and P = 0.0012 for tamoxifen). (c) MIN-O size at 10 weeks after transplantation. The ospemifene-treated and 
tamoxifen-treated MIN-Os were significantly smaller than the untreated MIN-Os 10 weeks after treatment (P < 0.0001). (d) Whole mounts of 
ospemifene-treated (left) and untreated (right) mammary fat pads at 10 weeks after transplantation. The untreated fat pad has a larger MIN-O area 
(dark blue). (e) Polyomavirus middle T (PyV-mT) expression in the MIN-Os was detected by immunohistochemistry with anti-PyV-mT antibody. 
Strong cytoplasmic expression of PyV-mT remained after the SERM treatment.
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mm3 ospemifene, 46 mm3 tamoxifen) than the control group
(167 mm3), a difference that approached statistical signifi-
cance (P = 0.12 and 0.14, respectively), while there was no
significant difference in mean tumor size between the SERM
groups. Moreover, the MIN-O size was significantly smaller in
both SERM groups than in the control group (P < 0.0001, Fig.
2c,d). The SERM treatment did not affect the intensity of the
cytoplasmic PyV-mT staining in the MIN-O epithelium (Fig. 2e).
Both ospemifene and its major metabolite, 4-hydroxy-
ospemifene, were found at biologically active concentrations
in the serum from the ospemifene-treated animals, while
tamoxifen and its major metabolite, N-desmethyl-tamoxifen,
were found at biologically active concentrations in the
tamoxifen-treated animals (data not shown). Ospemifene,
tamoxifen, and their two metabolites were not detected in the
control animals.
Immunohistochemical analysis of SERM-treated MIN-Os 
and tumors
ER expression in the treated and untreated tissues was exam-
ined by immunohistochemistry. We found that the tamoxifen
treatment resulted in decreased ER score (less intense and
less frequent) in the proliferating edges of the MIN-Os (Fig.
3a). Diminished ER expression by tamoxifen treatment has pre-
viously been reported in a Wnt-1 model [21]. Ospemifene
treatment, on the other hand, did not decrease the ER score;
rather, it increased the number of ER-positive cells in the MIN-
Os.
The architecture and morphology of the MIN-Os and tumors
did not differ among the groups, despite the differences in the
size of the lesions. SERM treatments, in general, resulted in
decreased proliferation and increased apoptosis. SERM-
treated MIN-Os retained the zone of increased proliferation at
the MIN-O/stroma interphase, but there were significantly
fewer Ki-67-positive cells in this zone in MIN-Os from the
tamoxifen treatment (P < 0.01) and ospemifene treatment (P
< 0.05) than in the control MIN-Os (Fig. 3b). The number of
apoptotic cells, visualized with antibody against cleaved cas-
pase-3, was increased in both ospemifene and tamoxifen-
treated MIN-Os but the differences were not statistically sig-
nificant (P = 0.198 and 0.4768 respectively, Fig. 3c).
Discussion
The study reported here is to our knowledge the first chemo-
prevention study to compare the efficacy of two SERMs, using
a transgenic mouse transplant model that fulfills the opera-
tional definition of premalignancy. We demonstrate that the
transplanted premalignant lesions (MIN-Os) are ER-positive
and their growth is ovarian-hormone-sensitive. Two related
SERMs, ospemifene and tamoxifen, had an inhibitory effect on
this mouse model for DCIS on the growth of premalignant
mammary lesions and on the tumor incidence. The primary
effect of these two agents was on proliferation, while apopto-
sis was less affected. In comparing the two SERMs, no signif-
icant differences were found in the growth of the premalignant
lesion, tumor incidence, and markers for proliferation or apop-
tosis. In contrast, there was a significant difference in the ER
status between the two SERM-treated groups. The ER score
in the MIN-O lesions was reduced after treatment with
tamoxifen but increased by treatment with ospemifene. Over-
all, these studies provide a foundation for studying and com-
paring the effects of hormonal manipulation in a
chemoprevention setting in an immunocompetent transplanta-
ble mouse model for DCIS.
The MIN-O line, 8w-B, originally isolated from dysplastic
lesions in the Tg(PyV-mT) mammary glands, was found to be
Figure 3
Immunohistochemistry analysis of mammary intraepithelial neoplasia outgrowths (MIN-Os) treated with selective estrogen receptor modulator (SERM)
(SERM). (a) Estrogen receptor (ER)-positive status was assessed by immunohistochemisty. ER positivity was slightly increased in ospemifene-
treated MIN-Os (P < 0.05) and significantly decreased by tamoxifen treatment (P = 0.0005). (b) The cell proliferation rate in SERM-treated MIN-Os 
was assessed by counting nuclei positive for the proliferation marker Ki-67 in a 40× field. Cell proliferation was in general decreased by the SERM 
treatments (P < 0.05 for ospemifene and P < 0.01 for tamoxifen). (c) SERM treatments slightly increased the averaged apoptotic cell number in the 
MIN-Os but the differences were not statistically significant (P = 0.198 for ospemifene and P = 0.4768 for tamoxifen).
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Recent studies with Tg(PyV-mT) mice have demonstrated that
the distribution and number of ER-positive cells change with
progression to malignancy [5]. In our studies, we observed a
specific distribution of ER-positive cells in the MIN-Os, show-
ing a higher ER score near the leading edge of the growing
outgrowth. Tumors, on the contrary, typically had cells with
weak ER positivity randomly scattered throughout the tumor.
To functionally assess this observation that the MIN-O is estro-
gen-positive, the host animals were ovariectomized to study
the effect on MIN-O growth and tumor incidence. Ovariectomy
significantly reduced the growth of the MIN-O and it signifi-
cantly increased the tumor latency. This data, coupled to the
receptor levels, suggests that MIN-O growth and progression
to invasive tumor is ovarian-hormone-dependent, albeit not
exclusively. This is reminiscent of human breast cancer, in
which oophorectomy decreases recurrence and the incidence
of contralateral invasive breast cancer [22,23].
Both SERMs exerted an inhibitory effect on the premalignant
tissue growth. As each initial transplant contains 1 mm3 of tis-
sue, the results at 3 weeks of treatment show that the trans-
plants are growing, albeit at a much slower rate. In addition,
this decreased growth effect is not due to decreased PyV-mT
expression in the treatment groups, as the PyV-mT expression
was not different between the SERM groups and the control
group, based on immunohistochemistry.
The SERMs also inhibited progression to invasive carcinoma.
Typically, a high proportion of the MIN-Os will have tumors by
10 weeks after transplantation. The SERM-treated animals
showed diminished MIN-O growth with significantly fewer
tumors than controls at this time point. The major effect of the
SERMs was on proliferation as seen by Ki-67 staining, rather
than on apoptosis. In human breast cancer, reduced Ki-67
staining is seen after treatment with SERMs and aromatase
inhibitors and has been used as efficacy marker in antiestro-
gen therapy [24]. No statistically significant differences in
MIN-O growth, tumor incidence, and rates of proliferation and
apoptosis were observed between the two SERM treatments.
One exception was the effect on ER expression. The
ospemifene treatment increased the ER score, whereas
tamoxifen decreased it. In ER-positive mammary tumors from
Wnt-1 transgenic mice, tamoxifen treatment resulted in
significant reduction of ER expression [21]. In a portion of
human tumors, decreased ER levels in tumors after tamoxifen
treatment has been shown to predict tamoxifen resistance
[25]. Therefore, these differences in ER modulation between
the two related SERMs may suggest different mechanisms of
action and may portend different long-term outcomes. This
may be reflected in the slight differences in cell proliferation
and apoptosis rate between the two treatment groups.
The study detailed here is the first to compare these two
related SERMs in a mouse mammary premalignant transplant
model and shows that ospemifene has equal effects to
tamoxifen in mammary lesions. This is important, because
ospemifene is currently in phase III clinical trials for urogenital
sequelae but limited data demonstrate its effectiveness in
breast cancer. As phase I and II studies have shown it was well
tolerated in healthy postmenopausal women, it may offer alter-
native hormonal options to women with breast cancer or at
high risk for breast cancer. In particular, ospemifene is not
known to cause menopausal symptoms, such as hot flashes,
insomnia, [26,27], melancholy, nervousness, dizziness, while it
has some proestrogenic effects on the bone [17] and vaginal
tissue [26] and, unlike other SERMs, does not cause vaginal
dryness. Recently, aromatase inhibitors have been shown to
provide better chemoprevention to the breast than tamoxifen,
but similar to tamoxifen, they have significant side effects
including bone loss, muscle and joint sequelae, and cardiac
events [15].
These studies provide evidence that both tamoxifen and
ospemifene have effects on decreasing growth and progres-
sion in our model of DCIS. Previously, the chemopreventive
effects of ospemifene have been studied in a dimethylbenz
[a]anthracene (DMBA)-induced rat and mouse tumor models,
where it reduced the incidence of mammary tumors [28].
Although the DMBA-induced models have been utilized by
many investigators in chemoprevention studies, they have sig-
nificant drawbacks in that they can only test the ability of an
agent to affect the progression to invasive carcinoma, rather
than examining the effects on the early preneoplastic disease.
In addition, the tumors that do arise from DMBA treatment are
commonly heterogeneous and involve many organs. Moreover,
a large portion of breast carcinomas derived in DMBA-treated
animals are adenocanthomas, which do not represent or
model typical human invasive carcinoma [29]. The chemopre-
ventive effects of tamoxifen have been studied in various
mouse models, including transgenic mice with activated neu
expression. In Tg(MMTV-neuN) mice, which exhibit estrogen-
sensitive tumor development [30,31], tamoxifen treatment
reduced the mammary tumor incidence and size when the
treatment was initiated before subclinical tumors had devel-
oped [32,33]. More recently, tamoxifen was shown to delay
tumorigenesis in an ER-positive Tg(P53-/-) mammary premalig-
nant transplant model [34].
The MIN-O model illustrated in these studies offers many
advantages over other mouse mammary carcinoma models for
chemoprevention studies. In typical transgenic mouse
mammary models, tumorigenesis occurs in a multifocal man-
ner, that is, multiple tumor foci develop in a mammary fat pad
arising independently and at different starting times. Thus, in a
given mammary fat pad, multiple lesions at different stages of
tumorigenesis can be seen. Since no two fat pads are the
same with respect to the development of the lesions, interpret-
ing the results of chemopreventative interventions can be very
complicated. Moreover it may require a significant amount of
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R888animals to distinguish the effect of an intervention. In contrast,
in the MIN-O model, the proliferation of the 'premalignant'
growth begins upon transplantation, and therefore the time to
malignant transformation is easily measurable.
Chemopreventative interventions can be applied before trans-
plantation, at transplantation, or at a defined time after the time
of transplantation. In particular, line 8w-B, a MIN-O line used
in this study, has a defined tumor latency period [2]. This rela-
tively short latency affords the opportunity to perform chemo-
prevention experiments rapidly. Secondly, the premalignant
MIN-O and the invasive tumor mimic the histopathology of,
respectively, human DCIS and invasive tumor [2,10]. Third,
since each experimental subject receives tissue from the same
MIN-O, the comparison of the experimental and control groups
is less prone to error due to differences in the biological
potential of the tissue. Fourth, the outgrowths continue to
maintain the same biological characteristics, such as tumor
latency, histopathological characteristics, and molecular pro-
files, over multiple serial transplant generations [2,3]. This phe-
notypic stability affords the opportunity to compare
experiments over time, regardless of the transplant generation.
Conclusion
The MIN-O line has the necessary biological and functional
characteristics to be utilized as a mouse model for preclinical
chemopreventive studies for human DCIS. This model, in an
immunocompetent animal, is ER-positive and progresses from
premalignant disease to invasive carcinoma. In particular, we
show that tamoxifen significantly reduces the growth rate and
tumor incidence of the 8w-B line. More importantly, we also
show that this model can be used to analyze a therapeutic
agent for which we have little data with respect to its chemo-
preventive effects in the breast. A promising result emerging
from this study is that ospemifene exhibits efficacy in breast
chemoprevention comparable to that of tamoxifen. Therefore,
this model provides a platform to investigate and compare the
effectiveness of antiestrogen agents, both as single agents
and potentially in combination with other synergistic agents.
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